PC
GYRE icon

PA Capital’s Gyre Therapeutics GYRE Stock Holding History

PA Capital’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$87K Buy
2,686
+521
+24% +$20.4K 0.06% 169
2020
Q2 		$95K Sell
2,165
-1,092
-34% -$51.3K 0.07% 160
2020
Q1 		$107K Hold
3,257
– – 0.09% 154
2019
Q4 		$166K Sell
3,257
-1,322
-29% -$55.4K 0.15% 118
2019
Q3 		$168K Buy
4,579
+408
+10% +$22K 0.17% 108
2019
Q2 		$231K Buy
4,171
+572
+16% +$35.7K 0.21% 93
2019
Q1 		$219K Buy
3,599
+200
+6% +$12.9K 0.2% 103
2018
Q4 		$201K Buy
+3,399
New +$251K 0.21% 95

Other funds holding GYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

PA Capital's GYRE Position: Q3 2020 in Review

PA Capital increased its Gyre Therapeutics (GYRE) stake by 24% in Q3 2020, buying an estimated $20.4K and bringing the position to 2,686 shares worth $87K. The position accounts for 0.06% of the portfolio, ranked #169.

PA Capital first reported a position in GYRE in Q4 2018 and has held it in 8 quarters since. The position peaked at $231K in Q2 2019. 78 funds tracked by Wall St. Rank hold GYRE as of Q3 2020.

  • PA Capital held 2,686 shares of Gyre Therapeutics worth $87K as of Q3 2020.
  • PA Capital bought 521 Gyre Therapeutics shares in Q3 2020, an estimated $20.4K.
  • Gyre Therapeutics made up 0.06% of PA Capital's portfolio in Q3 2020, its #169 holding.
  • PA Capital first reported a position in Gyre Therapeutics in Q4 2018 and has held it in 8 quarters since.
  • PA Capital's Gyre Therapeutics position peaked at $231K in Q2 2019.
  • 78 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q3 2020.

Based on PA Capital's 13F filing for Q3 2020, filed 13 Nov 2020.